Navigation Links
SuperGen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference on November 10, 2008
Date:11/3/2008

DUBLIN, Calif., Nov 3 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that James S. Manuso, Ph.D., President and Chief Executive Officer, is scheduled to present at the Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008, at the New York Palace Hotel.

SuperGen's presentation at the Rodman & Renshaw 10th Annual Healthcare Conference is scheduled to begin at 11:35 a.m. EDT (8:35 a.m. PDT). A live webcast of the presentation will be available on the investor relations section of the Company's Web site at http://www.supergen.com. The webcast will be archived for 90 days.

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Contacts:

SuperGen, Inc.

Timothy L. Enns

SVP, Corporate Communications

& Business Development

Tel: (925) 560-0100

Email: tenns@supergen.com

Mary M. Vegh

Manager, Investor Relations

Tel: (925) 560-2845

E-mail: mary.vegh@supergen.com

Dorland Global Public Relations

Michael Beckerich (Media)

Tel: (212) 677-7632

mbeckerich@dorland.com


'/>"/>
SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
2. SuperGen to Announce 2007 Third Quarter Financial Results October 29, 2007
3. SuperGen Reports 2007 Third Quarter Financial Results
4. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
5. SuperGen to Present at the Collins Stewart Growth Conference on July 9, 2008
6. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
7. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
8. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
9. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
10. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
11. AtriCure to Present at Roth Capital Partners 2007 New York Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:New Executive Leadership and CEO Announced for BiPar Sciences 2Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 2Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 3Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 4ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Cosmetic Use of Sculptra Now FDA Approved 54306 1Cosmetic Use of Sculptra Now FDA Approved 54306 2Cosmetic Use of Sculptra Now FDA Approved 54306 3Cosmetic Use of Sculptra Now FDA Approved 54306 4Nanosyn Inc and PCAS Announce the Signing of a Joint Venture Agreement to Operate PCAS NANOSYN LLC 13524 1Nanosyn Inc and PCAS Announce the Signing of a Joint Venture Agreement to Operate PCAS NANOSYN LLC 13524 2Nanosyn Inc and PCAS Announce the Signing of a Joint Venture Agreement to Operate PCAS NANOSYN LLC 13524 3Folk Medicine Therapy May Prevent Alcoholic Relapse 54302 1Folk Medicine Therapy May Prevent Alcoholic Relapse 54302 2